ストックスクリーナーアプリを入手
4.93
3.07%
-0.12
前日終値:
$5.05
開ける：
$4.98
24時間の取引高:
357.11K
Relative Volume:
0.41
時価総額：
$1.67B
収益：
$563.46M
当期純損益:
$27.92M
株価収益率:
51.14
EPS:
0.0964
ネットキャッシュフロー:
$-146.33M
1週間 パフォーマンス:
+22.68%
1か月 パフォーマンス:
+59.97%
6か月 パフォーマンス:
+17.67%
1年 パフォーマンス:
-39.72%
1日の値動き範囲:
$4.782
$4.98
1週間の範囲:
$3.75
$5.39
52週間の値動き範囲:
$2.94
$9.25
Alvotech Stock (ALVO) Company Profile
Compare ALVO vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
4.925 | 1.44B | 563.46M | 27.92M | -146.33M | 0.0964 |
TAK
Takeda Pharmaceutical Co Adr
|
18.27 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.21 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
37.39 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.79 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
517.52 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-09 | 開始されました | Barclays | Underweight |
| 2025-11-04 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2025-10-14 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-09-23 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-14 | 開始されました | UBS | Buy |
| 2024-01-29 | アップグレード | Barclays | Equal Weight → Overweight |
| 2023-10-20 | アップグレード | Citigroup | Sell → Neutral |
| 2023-09-21 | 開始されました | Barclays | Equal Weight |
| 2022-09-07 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-09-06 | ダウングレード | Citigroup | Buy → Sell |
| 2022-07-26 | 開始されました | Citigroup | Buy |
すべてを表示
Alvotech (ALVO) 最新ニュース
Teleconferência de Resultados do 2T26 da Alvotech (ALVO): Guidance Reafirmado - TradingKey
Alvotech (NASDAQ:ALVO) Builds Momentum Around Biosimilar Expansion - Kalkine Media
Alvotech 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ALVO) 2026-08-21 - Seeking Alpha
Alvotech, Lotus Ink Biosimilar Licensing and Commercialization Pact in US, Asia - Contract Pharma
Alvotech (NASDAQ:ALVO) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Alvotech licenses two early-stage biosimilar candidates to Lotus for USD 150m - AllSci
Alvotech (NASDAQ: ALVO) bets on U.S. biosimilars with Lotus - Stock Titan
Alvotech Enters Licensing, Commercialization Deal for Two Biosimilars in US, Certain Asian Markets - marketscreener.com
Alvotech Enters Strategic Licensing and Commercialization Agreement with Lotus Pharmaceutical for AVT34 and AVT87 - Quiver Quantitative
Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for ... - Enidnews.com
Alvotech and Lotus sign deal for proposed versions of $6.1B and $5.8B medicines - Stock Titan
Alvotech Q2 2026 Earnings Call Transcript - Sahm
Alvotech (ALVO) Stock Rises On Guidance Resolve Despite Lingering Loss Risk - simplywall.st
Alvotech Files H1 2026 Results and Schedules Business Update Call - The Globe and Mail
Alvotech holds rating despite H1 2026 earnings miss and FDA delays, eyes multiple biosimilar approvals by Q4 2026. - Pluang
Alvotech earnings missed by $0.02, revenue fell short of estimates - Investing.com India
Alvotech: Reiterate Hold On AVT05/AVT06 BLA Resubmissions And Upcoming Catalysts (ALVO) - Seeking Alpha
Alvotech (NASDAQ:ALVO) Trading 6.8% HigherHere's What Happened - MarketBeat
Alvotech Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: Alvotech misses Q2 2026 estimates as revenue stalls - Investing.com
ALVO: Revenue and margins set to rebound in H2 as supply normalizes and portfolio expands - TradingView
Alvotech Q2 2026 Earnings Call Summary - Yahoo Finance
Alvotech Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
Alvotech 1H Adjusted EBITDA $46.9 M >ALVO - Moomoo
Alvotech (ALVO) reports Q2 loss, beats revenue estimates - FXStreet
Alvotech (ALVO) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Iceland's Alvotech H1 revenue falls 31% on manufacturing program - TradingView
Alvotech (NASDAQ:ALVO) Releases Earnings Results, Misses Estimates By $0.17 EPS - MarketBeat
ALVOTECH ($ALVO) Releases Q2 2026 Earnings - Quiver Quantitative
Alvotech Q2 Results: EPS Misses Estimate, Sales Fall 39% YoY - scanx.trade
Alvotech H1 Results: Revenue falls 31%, EBITDA down 13% - scanx.trade
Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update - The Manila Times
Alvotech affirms FY26 sales guidance of $650M-$700M - scanx.trade
ALVO: Revenue and EBITDA fell in H1 2026, but outlook is strong as manufacturing recovers - TradingView
Alvotech H1 Reports Product Revenue USD 211.9 Million - TradingView
Alvotech (ALVO) raises $165M amid revenue drop and $72M interest hit - Stock Titan
Alvotech Announces Financial Results for the - Moomoo
Alvotech raises about $165 million as FDA decisions are expected in Q4 - Stock Titan
Alvotech earnings on deck as FDA biosimilar decisions loom By Investing.com - Investing.com India
Alvotech earnings on deck as FDA biosimilar decisions loom - Investing.com
Earnings To Watch: Alvotech (ALVO) Q2 2026 -- GF Value Sees 461% Upside - Yahoo Finance
Alvotech Hires CGCN Group on Pharma Tariffs - Legis1
Earnings To Watch: Alvotech (ALVO) Q2 2026 -- GF Value Sees 471% Upside - Yahoo Finance
ALVO Q2'26 Earnings: EPS estimate is (0.05) USD - TradingView
Alvotech (NASDAQ:ALVO) Shares Down 6.7%What's Next? - MarketBeat
Alvotech SA expected to post a loss of 3 cents a shareEarnings Preview - TradingView
Long term debt to total equity ratio of Alvotech Swedish Depository Receipt Repr 1 Sh – TURQUOISE:ALVOS - TradingView
Alvotech to Report Financial Results for H1 2026 - 富途牛牛
Alvotech (Z45) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Alvotech (Z45) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
Alvotech (Z45) Q2 2025 Earnings ReportResults, Call & Slides - tipranks.com
Alvotech (ALVO) 財務データ
収益
当期純利益
現金流量
EPS
0.37%
0.55%
大文字化:
|
ボリューム (24 時間):